Roth Capital Initiates Coverage On Nautilus Biotechnology with Buy Rating, Announces Price Target of $3.5

Roth Capital analyst Max Masucci has initiated coverage on Nautilus Biotechnology (NASDAQ: NAUT) with a Buy rating. The firm has set a price target of $3.50 for the stock.